{"resourceType": "Citation", "contained": [{"resourceType": "Practitioner", "id": "author0", "name": [{"family": "Botrel", "given": "Tobias Engel Ayer"}]}, {"resourceType": "Practitioner", "id": "author1", "name": [{"family": "Clark", "given": "Ot\u00e1vio"}]}, {"resourceType": "Practitioner", "id": "author2", "name": [{"family": "Lima Pompeo", "given": "Ant\u00f4nio Carlos"}]}, {"resourceType": "Practitioner", "id": "author3", "name": [{"family": "Horta Bretas", "given": "Francisco Fl\u00e1vio"}]}, {"resourceType": "Practitioner", "id": "author4", "name": [{"family": "Sadi", "given": "Marcus Vinicius"}]}, {"resourceType": "Practitioner", "id": "author5", "name": [{"family": "Ferreira", "given": "Ubirajara"}]}, {"resourceType": "Practitioner", "id": "author6", "name": [{"family": "Borges Dos Reis", "given": "Rodolfo"}]}, {"resourceType": "ArtifactAssessment", "id": "meshHeading0", "artifactReference": {"reference": "#", "type": "Citation"}, "content": [{"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D000368", "display": "Aged", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D000726", "display": "Androgen Antagonists", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "Q000627", "display": "therapeutic use"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "https://ncithesaurus.nci.nih.gov/ncitbrowser", "display": "Yes"}]}]}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D000970", "display": "Antineoplastic Agents", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "Q000627", "display": "therapeutic use"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "https://ncithesaurus.nci.nih.gov/ncitbrowser", "display": "Yes"}]}]}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D000971", "display": "Antineoplastic Combined Chemotherapy Protocols", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "Q000627", "display": "therapeutic use"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "https://ncithesaurus.nci.nih.gov/ncitbrowser", "display": "Yes"}]}]}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D000077143", "display": "Docetaxel", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D006801", "display": "Humans", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D008207", "display": "Lymphatic Metastasis", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D008297", "display": "Male", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D008875", "display": "Middle Aged", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D061214", "display": "Patient Safety", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D011471", "display": "Prostatic Neoplasms", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "Q000188", "display": "drug therapy"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "https://ncithesaurus.nci.nih.gov/ncitbrowser", "display": "Yes"}]}]}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "Q000401", "display": "mortality"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49487", "system": "https://ncithesaurus.nci.nih.gov/ncitbrowser", "display": "No"}]}]}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "Q000473", "display": "pathology"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49487", "system": "https://ncithesaurus.nci.nih.gov/ncitbrowser", "display": "No"}]}]}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D016032", "display": "Randomized Controlled Trials as Topic", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D016019", "display": "Survival Analysis", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D043823", "display": "Taxoids", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "Q000627", "display": "therapeutic use"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "https://ncithesaurus.nci.nih.gov/ncitbrowser", "display": "Yes"}]}]}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D016896", "display": "Treatment Outcome", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}]}, {"informationType": "classifier", "type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH heading"}], "text": "components (if present) include qualifier codings"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D050257", "display": "Tubulin Modulators", "userSelected": false}]}], "freeToShare": true, "component": [{"type": {"text": "qualifier"}, "classifier": [{"text": "is not a major topic"}]}, {"type": {"text": "qualifier"}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "Q000627", "display": "therapeutic use"}]}], "component": [{"type": {"text": "is Major topic"}, "classifier": [{"coding": [{"code": "C49488", "system": "https://ncithesaurus.nci.nih.gov/ncitbrowser", "display": "Yes"}]}]}]}]}]}], "useContext": [{"code": {"system": "http://hl7.org/fhir/citation-classification-type", "code": "fevir-platform-use", "display": "FEvIR Platform Use"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "medline-base", "display": "Medline Base", "userSelected": false}]}}], "classification": [{"type": {"coding": [{"system": "http://hl7.org/fhir/citation-classification-type", "code": "citation-source", "display": "Citation Source"}]}, "classifier": [{"text": "MEDLINE"}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/citation-classification-type", "code": "medline-owner", "display": "MEDLINE Citation Owner"}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value", "code": "NLM", "display": "National Library of Medicine, Index Section", "userSelected": false}]}]}], "statusDate": [{"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-received", "display": "PubMed Pubstatus of Received"}]}, "period": {"end": "2016-04-01"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-accepted", "display": "PubMed Pubstatus of Accepted"}]}, "period": {"end": "2016-06-02"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-entrez", "display": "PubMed Pubstatus of Entrez"}]}, "period": {"end": "2016-06-17T06:00:00.000Z"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-pubmed", "display": "PubMed Pubstatus of Pubmed"}]}, "period": {"end": "2016-06-17T06:00:00.000Z"}}, {"activity": {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-pubstatus-medline", "display": "PubMed Pubstatus of Medline"}]}, "period": {"end": "2017-07-27T06:00:00.000Z"}}], "citedArtifact": {"identifier": [{"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "27308831"}, {"system": "https://www.ncbi.nlm.nih.gov/pmc/", "value": "PMC4911003"}, {"system": "https://doi.org", "value": "10.1371/journal.pone.0157660"}, {"type": {"text": "pii"}, "value": "PONE-D-16-10077"}], "title": [{"text": "Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.", "language": {"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}, "type": [{"coding": [{"system": "http://hl7.org/fhir/title-type", "code": "primary", "display": "Primary title"}]}]}], "abstract": [{"text": "<AbstractText Label=\"OBJECTIVE\" NlmCategory=\"OBJECTIVE\">Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT \u00b1 docetaxel) for metastatic hormone-naive prostate cancer (mHNPC).</AbstractText><AbstractText Label=\"METHODS\" NlmCategory=\"METHODS\">Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI).</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p&lt;0.00001), and no heterogeneity (Chi2 = 0.64; df = 1 [p = 0.42]; I2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p&lt;0.00001), also with no heterogeneity noted (Chi2 = 0.48; df = 2 [p = 0.79]; I2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p&lt;0.0001), with moderate heterogeneity (Chi2 = 3.84; df = 2 [p = 0.15]; I2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade \u22653), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue.</AbstractText><AbstractText Label=\"CONCLUSION\" NlmCategory=\"CONCLUSIONS\">The combination of ADT with docetaxel improved the clinical progression-free survival, bPFS and OS of patients with mHNPC. A superior OS was seen especially for patients with metastatic and high-volume disease. This contemporary combination therapy may now be offered as a first-line treatment for selected patients.</AbstractText>"}], "relatesTo": [{"type": "cites", "citation": "http://clinicaltrials.gov/ct2/show/NCT00514540."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60(2):279\u201390. Epub 2011/05/20. doi: S0302-2838(11)00477-5 [pii] 10.1016/j.eururo.2011.04.038 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/21592649/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "21592649", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, et al. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. International braz j urol: official journal of the Brazilian Society of Urology. 2012;38(6):717\u201327. Epub 2013/01/11. .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/23302410/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23302410", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596\u2013605. Epub 2007/04/04. doi: JCO.2006.10.1949 [pii] 10.1200/JCO.2006.10.1949 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/17404365/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "17404365", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology. 2014;65(2):467\u201379. Epub 2013/12/11. 10.1016/j.eururo.2013.11.002 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/24321502/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "24321502", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69\u201377. Epub 2015/07/25. 10.1093/annonc/mdv222 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/26205393/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26205393", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004;11(2):103\u20139. Epub 2004/01/07. .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/14706014/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "14706014", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004;351(15):1513\u201320. Epub 2004/10/08. 10.1056/NEJMoa041318 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/15470214/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "15470214", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004;351(15):1502\u201312. Epub 2004/10/08. 10.1056/NEJMoa040720 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/15470213/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "15470213", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660\u20137. Epub 2015/05/24. 10.1093/annonc/mdv245", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/26002607/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26002607", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149\u201358. Epub 2013/01/12. 10.1016/s1470-2045(12)70560-0 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/23306100/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23306100", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naive metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial. 2015 Genitourinary Cancers Symposium Abstract 140 Presented February 26, 2015."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European urology. 2015. Epub 2015/11/28. 10.1016/j.eururo.2015.11.005 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/26610858/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26610858", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015;373(8):737\u201346. Epub 2015/08/06. 10.1056/NEJMoa1503747", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/26244877/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26244877", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s, 2014. (suppl; abstr LBA2)."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286\u201391. Epub 1994/11/12. .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/7718048/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "7718048", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Clarke M, Oxman AD, (Editors). Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software.2000."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999;117(3):138\u20139. Epub 1999/10/08. doi: S1516-3180(99)11700311 [pii]. .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/10511734/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "10511734", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. London: BMJ Books; 2001."}, {"type": "cites", "citation": "Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815\u201334. Epub 1999/01/28. [pii]. .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/9921604/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9921604", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. Epub 2003/09/06. 10.1136/bmj.327.7414.557 327/7414/557 [pii].", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/12958120/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "12958120", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010;30(4):229\u201341. Epub 2010/03/17. doi: 2 [pii] 10.2165/11532260-000000000-00000 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/20225906/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "20225906", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Deeks JJ, Higgins JP, Altman DG. Analysing and presenting results In: Higgins JP, G S editor. Cochrane Handbook for Systematic Reviews of In- terventions (ed 426 [updated September 2006]). Chichester, United Kingdom: John Wiley & Sons Ltd; 2006."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. Epub 1986/09/01. doi: 0197-2456(86)90046-2 [pii]. .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/3802833/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "3802833", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. Epub 1997/10/06.", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/9310563/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9310563", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712\u201320. Epub 1997/05/01. .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/9139558/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "9139558", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses\u2014sometimes informative, usually misleading. BMJ. 1999;318(7197):1548\u201351. Epub 1999/06/04.", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/10356018/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "10356018", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3 Epub 2002/02/28.", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/11860606/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "11860606", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65\u201394. Epub 2009/07/23. doi: 0000605-200908180-00136 [pii].", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/19622512/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "19622512", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. The Lancet Oncology. 2015;16(7):787\u201394. Epub 2015/06/02. 10.1016/s1470-2045(15)00011-x .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/26028518/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26028518", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, et al. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013;81(3):611\u20136. Epub 2013/03/05. 10.1016/j.urology.2012.12.025 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/23452809/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23452809", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. Journal of hematology & oncology. 2014;7:20 Epub 2014/03/07. 10.1186/1756-8722-7-20", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/24598155/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "24598155", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. European urology. 2012;62(2):213\u20139. Epub 2012/04/17. 10.1016/j.eururo.2012.03.053 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/22502942/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "22502942", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (London, England). 2011;378(9809):2104\u201311. Epub 2011/11/08. 10.1016/s0140-6736(11)61095-7", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/22056152/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "22056152", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (London, England). 2009;373(9660):301\u20138. Epub 2008/12/19. 10.1016/s0140-6736(08)61815-2 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/19091394/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "19091394", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer chemotherapy and pharmacology. 2013;71(6):1629\u201334. Epub 2013/04/23. 10.1007/s00280-013-2163-4 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/23604530/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23604530", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Rajan P, Frew JA, Wilson JM, Azzabi AS, McMenemin RM, Stockley J, et al. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urol Oncol. 2015;33(8):337.e1\u20136. Epub 2015/06/21. 10.1016/j.urolonc.2015.05.012 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/26092557/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26092557", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the \"Docetaxel Era\": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European urology. 2015;67(6):1028\u201338. Epub 2014/10/11. 10.1016/j.eururo.2014.09.032 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/25301760/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "25301760", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "James ND, Sydes MR, Mason M, et al. Docetaxel and/or zoledronic acid for hormone-na\u00efve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 33, 2015. (suppl; abstr 5001)."}, {"type": "cites", "citation": "Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, et al. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J Clin Oncol 34, 2016. (suppl 2S; abstr 286)."}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 2008;88(1):1\u20139. Epub 2008/05/27. doi: S0167-8140(08)00233-8 [pii] 10.1016/j.radonc.2008.04.013 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/18501455/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "18501455", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589\u2013604. Epub 2015/06/05. 10.1093/annonc/mdv257", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/26041764/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "26041764", "assigner": {"display": "NLM"}}}}, {"type": "cites", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article"}]}], "citation": "Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The Lancet Oncology. 2013;14(2):117\u201324. Epub 2013/01/09. 10.1016/s1470-2045(12)70537-5 .", "document": {"url": "https://pubmed.ncbi.nlm.nih.gov/23294853/"}, "resourceReference": {"identifier": {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "23294853", "assigner": {"display": "NLM"}}}}, {"type": "cites", "citation": "Kellokumpu-Lehtinen PL, Harmenberg U, Hervonen P, Joensuu TK, McDermott RS, Ginman C, et al. Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis. J Clin Oncol 32, 2014. (suppl 4; abstr 23)."}, {"type": "cites", "citation": "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf."}, {"type": "cites", "citation": "Liaw BC, Oh WK. Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer? The American Journal of Hematology/oncology 2015; 11(9):17\u201320"}], "publicationForm": [{"publishedIn": {"type": {"coding": [{"system": "http://hl7.org/fhir/published-in-type", "code": "D020492", "display": "Periodical"}]}, "identifier": [{"type": {"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn", "code": "Electronic", "display": "Electronic"}], "text": "Electronic ISSN Type"}, "value": "1932-6203", "system": "https://portal.issn.org"}, {"type": {"text": "ISOAbbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.issn.org/services/online-services/access-to-the-ltwa/", "value": "PLoS One"}, {"type": {"text": "ISSN Linking", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/", "value": "1932-6203"}, {"type": {"text": "Medline Title Abbreviation", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html", "value": "PLoS One"}, {"type": {"text": "NLM Unique ID", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "XX", "display": "Organization identifier"}]}, "system": "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local", "value": "101285081"}], "title": "PloS one", "publisherLocation": "United States"}, "citedMedium": {"coding": [{"system": "http://hl7.org/fhir/cited-medium", "code": "internet", "display": "Internet"}]}, "volume": "11", "issue": "6", "articleDate": "2016", "language": [{"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}], "pageString": "e0157660", "publicationDateText": "2016"}, {"citedMedium": {"coding": [{"system": "http://hl7.org/fhir/cited-medium", "code": "internet-without-issue", "display": "Internet without issue"}]}, "articleDate": "2016-06-16"}], "webLocation": [{"classifier": [{"coding": [{"system": "http://hl7.org/fhir/artifact-url-classifier", "code": "abstract", "display": "Abstract"}]}], "url": "https://pubmed.ncbi.nlm.nih.gov/27308831/"}, {"url": "https://doi.org/10.1371/journal.pone.0157660", "classifier": [{"coding": [{"system": "http://hl7.org/fhir/artifact-url-classifier", "code": "doi-based", "display": "DOI Based"}]}]}], "classification": [{"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "publishing-model", "display": "Publishing Model", "userSelected": false}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "Electronic-eCollection", "display": "Electronic-eCollection", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "chemical", "display": "Chemical", "userSelected": false}]}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D000726", "display": "Androgen Antagonists", "userSelected": false}]}, {"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D000970", "display": "Antineoplastic Agents", "userSelected": false}]}, {"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D043823", "display": "Taxoids", "userSelected": false}]}, {"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D050257", "display": "Tubulin Modulators", "userSelected": false}]}, {"coding": [{"system": "https://www.cas.org/support/documentation/chemical-substances", "code": "15H5577CQD", "userSelected": false}, {"system": "https://meshb.nlm.nih.gov/", "code": "D000077143", "display": "Docetaxel", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "mesh-heading", "display": "MeSH Heading"}]}, "artifactAssessment": [{"reference": "#meshHeading0", "type": "ArtifactAssessment"}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "publication-type", "display": "Publication Type"}]}, "classifier": [{"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D016428", "display": "Journal Article", "userSelected": false}]}, {"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D017418", "display": "Meta-Analysis", "userSelected": false}]}, {"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D016454", "display": "Review", "userSelected": false}]}, {"coding": [{"system": "https://meshb.nlm.nih.gov/", "code": "D000078182", "display": "Systematic Review", "userSelected": false}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "knowledge-artifact-type", "display": "Knowledge Artifact Type", "userSelected": false}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/citation-artifact-classifier", "code": "D016428", "display": "Journal Article", "userSelected": false}]}], "artifactAssessment": [{"display": "Classifier added by Computable Publishing LLC"}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/cited-artifact-classification-type", "code": "citation-subset", "display": "Citation Subset", "userSelected": false}]}, "classifier": [{"coding": [{"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset", "code": "IM", "display": "IM", "userSelected": false}]}]}], "contributorship": {"entry": [{"contributor": {"reference": "#author0", "type": "Practitioner", "display": "Botrel TE"}, "forenameInitials": "TE", "affiliation": [{"display": "Evidencias - A Kantar Health Company, Campinas, S\u00e3o Paulo, Brazil."}, {"display": "Comit\u00ea Brasileiro de Estudos em Uro-Oncologia - CoBEU, S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}]}, {"contributor": {"reference": "#author1", "type": "Practitioner", "display": "Clark O"}, "forenameInitials": "O", "affiliation": [{"display": "Evidencias - A Kantar Health Company, Campinas, S\u00e3o Paulo, Brazil."}, {"display": "Comit\u00ea Brasileiro de Estudos em Uro-Oncologia - CoBEU, S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}]}, {"contributor": {"reference": "#author2", "type": "Practitioner", "display": "Lima Pompeo AC"}, "forenameInitials": "AC", "affiliation": [{"display": "Comit\u00ea Brasileiro de Estudos em Uro-Oncologia - CoBEU, S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}]}, {"contributor": {"reference": "#author3", "type": "Practitioner", "display": "Horta Bretas FF"}, "forenameInitials": "FF", "affiliation": [{"display": "Comit\u00ea Brasileiro de Estudos em Uro-Oncologia - CoBEU, S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}]}, {"contributor": {"reference": "#author4", "type": "Practitioner", "display": "Sadi MV"}, "forenameInitials": "MV", "affiliation": [{"display": "Comit\u00ea Brasileiro de Estudos em Uro-Oncologia - CoBEU, S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}]}, {"contributor": {"reference": "#author5", "type": "Practitioner", "display": "Ferreira U"}, "forenameInitials": "U", "affiliation": [{"display": "Comit\u00ea Brasileiro de Estudos em Uro-Oncologia - CoBEU, S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}]}, {"contributor": {"reference": "#author6", "type": "Practitioner", "display": "Borges Dos Reis R"}, "forenameInitials": "R", "affiliation": [{"display": "Comit\u00ea Brasileiro de Estudos em Uro-Oncologia - CoBEU, S\u00e3o Paulo, S\u00e3o Paulo, Brazil."}]}], "complete": true}}, "lastReviewDate": "2022-03-17", "currentState": [{"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "medline-medline", "display": "Medline Citation Status of Medline"}]}, {"coding": [{"system": "http://hl7.org/fhir/citation-status-type", "code": "pubmed-publication-status-epublish", "display": "PubMed PublicationStatus of epublish"}]}], "title": "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "179613", "assigner": {"display": "Computable Publishing LLC"}}, {"system": "https://pubmed.ncbi.nlm.nih.gov", "value": "27308831"}], "status": "active", "meta": [{"versionId": "1", "lastUpdated": "2023-11-26T18:47:26.987Z"}], "url": "https://fevir.net/resources/Citation/179613", "id": "179613", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Computable Publishing\u00ae: MEDLINE-to-FEvIR Converter"}], "approvalDate": "2017-07-26"}